The SLC17A6 antibody targets the solute carrier family 17 member 6 (SLC17A6) protein, also known as vesicular glutamate transporter 2 (VGluT2). This transporter is primarily responsible for packaging the excitatory neurotransmitter glutamate into synaptic vesicles, a critical step in glutamatergic neurotransmission. VGluT2 is one of three vesicular glutamate transporters (VGluT1-3) and is predominantly expressed in subcortical regions of the central nervous system, including the thalamus, brainstem, and cerebellum, distinguishing it from VGluT1 (cortical/hippocampal) and VGluT3 (serotonergic/other neurons).
Antibodies against SLC17A6/VGluT2 are widely used in neuroscience research to identify and map glutamatergic neurons, study synaptic plasticity, and investigate neural circuits involved in sensory processing, motor control, and behavior. They are essential tools for immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting (WB) applications. The specificity of SLC17A6 antibodies is often validated using knockout models or comparative analyses with other VGluT isoforms to ensure minimal cross-reactivity.
Research applications extend to neurodegenerative diseases (e.g., Alzheimer's, Parkinson's), psychiatric disorders (e.g., schizophrenia), and pain pathways, where glutamatergic dysregulation is implicated. Commercial SLC17A6 antibodies are typically raised in hosts like rabbit or mouse, with validation emphasizing tissue-specific staining patterns consistent with known VGluT2 expression. Proper controls, such as knockout validation or peptide blocking, are recommended to confirm antibody reliability in experimental setups.